Understand the source comparison
Lyme Disease Peptides 2026 Update: Comparison with Antibiotics and Other Treatments
Thymosin Alpha-1 (1.6mg 2×/week) T-cell regulation, Treg activation, cytokine suppression 67% met primary endpoint (≥30% symptom reduction) Subcutaneous injection $2,400–$3,200 (compounded) Phase 2 RCT, peer-reviewed Extended Doxycycline (200mg daily × 90 days
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Alpha-1 (1.6mg 2×/week)
- T-cell regulation, Treg activation, cytokine suppression
- 67% met primary endpoint (≥30% symptom reduction)
- Subcutaneous injection
- $2,400–$3,200 (compounded)
- Phase 2 RCT, peer-reviewed
- Extended Doxycycline (200mg daily × 90 days)
- Bacterial protein synthesis inhibition
- No benefit over placebo in PTLDS cohort
- Oral
- $180–$350 (generic)
- Phase 2 RCT (Johns Hopkins), no superiority shown
- Ceftriaxone IV (2g daily × 28 days)
- Bacterial cell wall synthesis inhibition
- Mixed results; fatigue improved 23% vs 18% placebo (not statistically significant)
- Intravenous infusion
- $8,000–$12,000 (with home health)
- Phase 3 data (Fallon 2008), endpoints not met
- Combination Antibiotics (doxy + azithro + tinidazole)
- Multi-target bacterial inhibition
- No controlled trial data; case series only
- $600–$1,200
- Observational only, no RCT
- Immune Support Supplements (vitamin D, omega-3)
- General anti-inflammatory effects
- No specific PTLDS trials; baseline deficiency correction may help
- $100–$300
- No controlled data in PTLDS
- Professional Assessment
- Peptides address immune dysregulation antibiotics can't reach. Extended antibiotics showed no benefit in controlled settings. IV ceftriaxone remains unproven for PTLDS. Peptides represent the first intervention with statistically significant symptom reduction in a placebo-controlled trial.
- The Johns Hopkins head-to-head comparison is the critical data point: patients randomised to extended doxycycline showed identical outcomes to placebo at 12 weeks. Serum antibody titers (IgM, IgG) did not predict response. PTLDS is not driven by active infection. Peptides reduced symptoms without changing antibody levels, confirming the mechanism is immune modulation, not pathogen clearance.